erlotinib hydrochloride

erlotinib hydrochloride

(ĕr′lō′tə-nĭb)
n.
A tyrosine kinase inhibitor used in the treatment of certain forms of non-small cell lung cancer and pancreatic cancer.
Mentioned in ?
References in periodicals archive ?
Erlotinib hydrochloride (ERLO) is an epidermal growth factor receptor inhibitor that was approved by the United States Food and Drug Administration (FDA) in 2004 for the treatment of non-small-cell lung cancer and its anticancer effects promised hope in various preclinical models.
Bioequvalence of new generic formulation of erlotinib hydrochloride 150 mg tablets versus Tarceva[R] in healthy volunteers under fasting conditions.
Contract award notice: : erlotinib hydrochloride 2016.
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Medicine with drug Erlotinib Hydrochloride, ATC L01XE03.
Prior Information Notice without call for competition:Provision of Erlotinib hydrochloride
Medicine with drug Erlotinib Hydrochloride, ATC L01XE03.estimated value excluding VAT: 6,000,000 CZK